Slide 1: Cover letter to stock exchanges: Q1 FY23 Earnings Call presentation
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com July 28, 2022 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate
Slide 2: Q1FY23 Earnings Call
Q1FY23 Earnings Call July 28, 2022 Classified as Restricted B I O C O N L I M I T E D 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Q1FY23 Earnings Call
Q1FY23 Earnings Call Classified as Restricted B I O C O N L I M I T E D 33
Slide 5: Opening Remarks
Opening Remarks Every economy is trying to offset pandemic spend impact by lowering healthcare spend India - key role in driving inclusive & equitable growth, particularly in healthcare Continued investments in capacities, capabilities and R&D to enable Biocon to be a biopharmaceuticals leader ESG -
Slide 6: Organizational Announcements
Organizational Announcements Classified as Restricted B I O C O N L I M I T E D 55
Slide 7: Board Updates: Independent Directors complete second term of tenure
Board Updates : Independent Directors complete second term of tenure Mary Harney, Independent Director – Biocon Limited Member of the Board from 2012 - 2022 - Expertise in Global Healthcare, Research and Innovation and Corporate Governance & Compliance - Last served as Chairperson of Biocon Limited’
Slide 8: Management Update: Biocon Biologics
Management Update : Biocon Biologics Michael Cutter, Chief Quality Officer – Biocon Biologics - Responsible for leading global Quality organization across all locations - Based in Bangalore - Over three decades of experience across Quality Control, Quality Assurance and Pharmaceutical Manufacturing,
Slide 9: Q1FY23 Financial Highlights
Q1FY23 Financial Highlights Classified as Restricted B I O C O N L I M I T E D 88
Slide 10: Financial Highlights: Q1FY23
Financial Highlights: Q1FY23 Q1FY23 Q1FY22 Biosimilars +29% | Generics +19% | Revenue +23% ₹2,217Cr ₹1,808Cr Research Services +8% Core EBITDA* +25% ₹660Cr ₹530Cr Forex Loss of ₹38Cr vs Gain of ₹17Cr in Q1FY22 % margin 31% 30% Gross R&D spend at ₹223Cr vs ₹136Cr in EBITDA +9% ₹478Cr ₹437Cr Q1FY22 R&
Slide 11: Q1FY23 Generics
Q1FY23 Generics Classified as Restricted B I O C O N L I M I T E D 10 10
Slide 12: Generics: Q1FY23 Update
Generics: Q1FY23 Update KEY HIGHLIGHTS Q1FY23 Q1FY23 YoY growth due to continued performance in API & recently launched generic formulations, coupled with lower base last year Revenue ₹580Cr ₹486Cr +19% Launched vertically integrated formulation, Mycophenolic Acid Delayed Release tablet in the US Re
Slide 13: Q1FY23 Biosimilars
Q1FY23 Biosimilars Classified as Restricted B I O C O N L I M I T E D 12 12
Slide 14: Biosimilars: Q1 FY23 Update
Biosimilars: Q1 FY23 Update KEY HIGHLIGHTS Q1FY23 Q1FY22 Revenue growth excluding COVID-19 related sales at 46% YoY Revenue ₹977Cr ₹758Cr +29% Progress of our unpartnered biosimilars pipeline, including bUstekinumab & bDenosumab, increased R&D cost by 120% YoY Core EBITDA* Non-cash foreign currency
Slide 15: Q1FY23 Novels
Q1FY23 Novels Classified as Restricted B I O C O N L I M I T E D 14 14
Slide 16: Novels: Q1 FY23 Update
Novels : Q1 FY23 Update KEY HIGHLIGHTS Equillium initiated patient dosing for the pivotal Phase III clinical study of Itolizumab in patients with aGVHD* Patient recruitment continues for the pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis Recommended dose established** at 1500 mg o
Slide 17: Q1FY23 Research Services
Q1FY23 Research Services Classified as Restricted B I O C O N L I M I T E D 16 16
Slide 18: Research Services: Q1FY23 Update
Research Services: Q1FY23 Update KEY HIGHLIGHTS Q4FY22 Q4FY21 Results against a strong quarter last year due to Remdesivir sales. Excluding Remdesivir, ~30%YoY revenue growth Revenue ₹645Cr ₹595Cr +8% Signed 10-year agreement with Zoetis for commercial manufacturing of drug substance for Librela®, M
Slide 19: Concluding Remarks
Concluding Remarks Classified as Restricted B I O C O N L I M I T E D 18 18
Slide 20: Q&A
Q&A Classified as Restricted B I O C O N L I M I T E D 19 19